GnRH Agonist Early Follicular Challenge Test As a Predictor of Ovarian Response in Antagonist Cycles for Fertility Preservation

Overview

Journal Sci Rep

Specialty Science

Date 2024 Jun 21

PMID 38906914

Authors

Gil M Yerushalmi

Sarit Avraham

Alon Kedem

Michal Youngster

Jonathan Barkat

Ohad Baruchin

Itai Gat

Odelia Yaakov

Yariv Gidoni

Ariel Hourvitz

Affiliations

Soon will be listed here.

Abstract

The aim of our study was to evaluate if the response to follicular GnRH agonist (GnRHa) trigger be used to predict intracycle ovarian response in GnRH antagonist cycles among women undergoing fertility preservation IVF. We conducted a prospective study of 146 GnRH antagonist oocyte pickup (OPU) cycles to evaluate GnRHa stimulation test (GAST). On day 2 of the cycle, basal E2 were measured, followed by injection of 0.2 mg GnRHa as part of the initial ovarian stimulation. 12 h later blood sampling was repeated (GAST E3). E2 response was used as test parameter. The major outcome was the number of mature cryopreserved oocytes. We found a linear correlation between both GAST E3 level and GAST E3/E2 ratio and number of M2 oocytes. ROC curve analysis of GAST E3, GAST E3/E2 ratio, AFC and day 3 FSH for > 15 M2 and < 5 M2 oocytes was calculated. For GAST E3 levels obtaining < 5 M2 oocytes, an AUC value of 0.79 was found. For GAST E3 levels obtaining > 15 M2 oocytes, AUC value of 0.8. Patients with GAST E3 ≤ 384 pmol/l has 58.6% risk to obtain < 5 oocytes. Patients younger than 35 with GAST E3 > 708 pmol/l have 66% chance for freezing > 15 oocytes. The response to single GnRHa administration during GnRH antagonist cycle can be used as biomarker of ovarian reserve. This simple, widely available marker, which reflect the estradiol response of small follicles, might predict the response of the specific cycle, and can potentially be used to adjust the treatment dose.Trial registration number: 0304-20-ASF.

References

La Marca A, Sunkara S . Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2013; 20(1):124-40. DOI: 10.1093/humupd/dmt037. View

La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio A . Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2009; 16(2):113-30. DOI: 10.1093/humupd/dmp036. View

Cedrin-Durnerin I, Herve F, Kottler M, Hugues J . Progestogen pretreatment in the short-term protocol does not affect the prognostic value of the oestradiol flare-up in response to a GnRH agonist. Hum Reprod. 1995; 10(11):2904-8. DOI: 10.1093/oxfordjournals.humrep.a135816. View

Jirge P . Ovarian reserve tests. J Hum Reprod Sci. 2012; 4(3):108-13. PMC: 3276943. DOI: 10.4103/0974-1208.92283. View

Broekmans F, Kwee J, Hendriks D, Mol B, Lambalk C . A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006; 12(6):685-718. DOI: 10.1093/humupd/dml034. View

Vuong T, Ho M, Ha T, Phung H, Huynh G, Humaidan P . Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study. Fertil Steril. 2015; 105(2):356-63. DOI: 10.1016/j.fertnstert.2015.10.014. View

Rombauts L, Lambalk C, Schultze-Mosgau A, van Kuijk J, Verweij P, Gates D . Intercycle variability of the ovarian response in patients undergoing repeated stimulation with corifollitropin alfa in a gonadotropin-releasing hormone antagonist protocol. Fertil Steril. 2015; 104(4):884-890.e2. DOI: 10.1016/j.fertnstert.2015.06.027. View

Richards J, Pangas S . The ovary: basic biology and clinical implications. J Clin Invest. 2010; 120(4):963-72. PMC: 2846061. DOI: 10.1172/JCI41350. View

Johnston M, Richings N, Leung A, Sakkas D, Catt S . A major increase in oocyte cryopreservation cycles in the USA, Australia and New Zealand since 2010 is highlighted by younger women but a need for standardized data collection. Hum Reprod. 2020; 36(3):624-635. DOI: 10.1093/humrep/deaa320. View

10.

Winslow K, Toner J, Brzyski R, Oehninger S, Acosta A, Muasher S . The gonadotropin-releasing hormone agonist stimulation test--a sensitive predictor of performance in the flare-up in vitro fertilization cycle. Fertil Steril. 1991; 56(4):711-7. DOI: 10.1016/s0015-0282(16)54604-4. View

11.

Avraham S, Youngster M, Yerushalmi G, Belov Y, Gat I, Kedem A . Follicular challenge test to predict suboptimal response to gonadotropin releasing hormone agonist trigger in elective oocyte cryopreservation cycles. Sci Rep. 2024; 14(1):6204. PMC: 10940571. DOI: 10.1038/s41598-024-56418-2. View

12.

Cobo A, Garcia-Velasco J, Remohi J, Pellicer A . Oocyte vitrification for fertility preservation for both medical and nonmedical reasons. Fertil Steril. 2021; 115(5):1091-1101. DOI: 10.1016/j.fertnstert.2021.02.006. View

13.

Lainas T, Zorzovilis J, Petsas G, Stavropoulou G, Cazlaris H, Daskalaki V . In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF. Hum Reprod. 2005; 20(9):2426-33. DOI: 10.1093/humrep/dei106. View

14.

McIlveen M, Skull J, Ledger W . Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Hum Reprod. 2006; 22(3):778-85. DOI: 10.1093/humrep/del435. View

15.

Hendriks D, Broekmans F, Bancsi L, Looman C, de Jong F, Te Velde E . Single and repeated GnRH agonist stimulation tests compared with basal markers of ovarian reserve in the prediction of outcome in IVF. J Assist Reprod Genet. 2005; 22(2):65-73. PMC: 3455479. DOI: 10.1007/s10815-005-1495-3. View

16.

Yildiz S, Yakin K, Ata B, Oktem O . There is a cycle to cycle variation in ovarian response and pre-hCG serum progesterone level: an analysis of 244 consecutive IVF cycles. Sci Rep. 2020; 10(1):15793. PMC: 7519678. DOI: 10.1038/s41598-020-72597-0. View

17.

Niederberger C, Pellicer A, Cohen J, Gardner D, Palermo G, ONeill C . Forty years of IVF. Fertil Steril. 2018; 110(2):185-324.e5. DOI: 10.1016/j.fertnstert.2018.06.005. View

18.

Orvieto R, Laufer N . Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for in vitro fertilization. Fertil Steril. 2014; 102(5):1254-5. DOI: 10.1016/j.fertnstert.2014.09.003. View

19.

Lashen H, Afnan M, McDougall L, Clark P . Prediction of over-response to ovarian stimulation in an intrauterine insemination programme. Hum Reprod. 1999; 14(11):2751-4. DOI: 10.1093/humrep/14.11.2751. View

20.

Broer S, Mol B, Hendriks D, Broekmans F . The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril. 2008; 91(3):705-14. DOI: 10.1016/j.fertnstert.2007.12.013. View